CD8A and neoplasm: To elucidate the tumor-infiltrating efficacy of tumor-specific T cells, the tumor was removed and intra-tumor CD45.2+ cells was analyzed by immunohistochemical staining at 16 hours after adoptive transfer of P14 CD8+ effector cells (CD45.2+) into tumor-bearing CD45.1 mice, (Figure 4A).